Crinetics pharmaceuticals, inc. (CRNX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating activities:
Net loss

-17,360

-14,549

-14,430

-12,427

-9,016

-8,495

-7,588

-5,568

-5,464

Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation

2,147

1,831

1,854

1,581

1,028

847

775

272

426

Depreciation and amortization

235

229

228

230

200

208

139

76

48

Noncash lease expense

65

60

57

56

53

-

-

-

-

Accretion of purchase discounts and amortization, net of premiums on investment securities

180

220

320

289

400

-

-

-

-

Other

19

7

-1

1

-3

-

65

-74

-2

Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets

-663

1,298

947

881

-905

632

-105

985

290

Accounts payable and accrued expenses

2,391

674

114

-675

583

2,881

828

1,781

1,871

Operating lease liability

-172

-167

-164

-162

-115

-

-

-

-

Net cash used in operating activities

-12,230

-13,447

-13,607

-12,568

-6,759

-6,009

-5,693

-4,350

-3,407

Investing activities:
Purchases of investment securities

22,886

41,066

14,406

21,101

31,563

-

-

-

-

Maturities of investment securities

39,285

28,271

34,854

30,600

56,570

-

-

-

-

Purchases of property and equipment

60

28

0

56

408

282

251

469

57

Net cash provided by investing activities

16,339

-12,823

20,448

9,443

24,599

-118,681

-251

-469

-57

Financing activities:
Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

9

0

-127

63,393

Proceeds from issuance of common stock, net

6,427

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

55

17

22

67

20

0

58

140

253

Payment of initial public offering costs

-

-

-

-

-

-

-

526

134

Net cash provided by financing activities

6,482

17

22

8

20

9

107,190

-513

63,512

Net change in cash, cash equivalents and restricted cash

10,591

-26,253

6,863

-3,117

17,860

-124,681

101,246

-5,332

60,048

Noncash investing and financing activities:
Change in unvested stock liability

10

177

-12

-124

53

35

-7

-4

-3

Amounts accrued for purchases of property and equipment

-

-

-

-

27

-104

94

-15

67

Change in accrued preferred stock issuance and initial public offering costs

-

-

-

-

-

-

-

-

301